Repare Therapeutics Inc. Common Shares (RPTX) is a publicly traded Healthcare sector company. As of May 21, 2026, RPTX trades at $2.65 with a market cap of $114.24M and a P/E ratio of -1.19. RPTX moved +0.38% today. Year to date, RPTX is +46.41%; over the trailing twelve months it is +130.44%. Its 52-week range spans $0.89 to $4.07. Analyst consensus is buy with an average price target of $3.00. Rallies surfaces RPTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Repare Therapeutics Shareholders Approve 99.76% Vote for XenoTherapeutics Acquisition: Repare Therapeutics shareholders approved XenoTherapeutics' acquisition of all common shares by 99.76% at a special meeting, including 99.34% support for related executive compensation. The arrangement, subject to Superior Court of Québec approval on January 23, 2026, is expected to close by January 28, 2026, pending customary conditions.
| Metric | Value |
|---|---|
| Price | $2.65 |
| Market Cap | $114.24M |
| P/E Ratio | -1.19 |
| EPS | $-2.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.07 |
| 52-Week Low | $0.89 |
| Volume | 1.22M |
| Avg Volume | 0 |
| Revenue (TTM) | $51.13M |
| Net Income | $-93.80M |
| Gross Margin | 0.00% |
9 analysts cover RPTX: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.00.